LIXTE's LB-100 Combined with GSK's Dostarlimab in Ovarian Clear Cell Carcinoma Study

Lixte Biotechnology Holdings, Inc., a pharmaceutical firm specializing in cancer drug development, has commenced a Phase 1b/2 clinical trial to investigate the potential of combining its LB-100 with GSK’s dostarlimab-gxly, a PD-1-blocking monoclonal antibody, for treating ovarian clear cell carcinoma (OCCC). The trial, initiated and conducted by The University of Texas MD Anderson Cancer Center, is based on the premise that a reduction in PP2A, a protein phosphatase, could increase the effectiveness of immunotherapy in patients with OCCC.

LIXTE is contributing LB-100 to the trial, while GSK is providing dostarlimab-gxly and financial support. The trial, registered as NCT06065462, is led by Amir Jazaeri MD, a Gynecologic Oncology Professor at MD Anderson, who has observed that genetically reduced PP2A levels may heighten sensitivity to immunotherapy. This suggests that LB-100, designed to pharmacologically reduce PP2A, could potentially enhance the efficacy of dostarlimab-gxly in treating OCCC patients.

LIXTE is a clinical-stage company with a focus on identifying novel targets for cancer therapies and bringing them to market. Their lead product, LB-100, has shown to be well-tolerated in patients and has demonstrated anti-cancer activity at administered doses. With robust preclinical data supporting its potential, LB-100 is poised to improve patient outcomes in various chemotherapy and immunotherapy settings. The company's innovative approach stands without competition and is protected by a comprehensive patent portfolio. LIXTE is currently engaged in proof-of-concept clinical trials to further validate the effectiveness of their lead compound.